^
    7ms
    Brystkreft hos menn – histopatologi og biomarkører. (PubMed, Tidsskr Nor Laegeforen)
    Our findings indicate that men with breast cancer are diagnosed at an older age than women, and that men have a more advanced stage than women at the time of diagnosis. The histopathology and expression of biomarkers of breast cancer differ between men and women.
    Retrospective data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • ER positive • PGR positive • PGR positive + HER-2 positive
    over1year
    Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor-Positive/ERBB2-Positive Early Breast Cancer: The Neoadjuvant WSG-TP-II Randomized Clinical Trial. (PubMed, JAMA Oncol)
    P2; Standard ET (aromatase inhibitor or tamoxifen) or paclitaxel, 80 mg/m2, weekly plus trastuzumab and pertuzumab every 21 days. The WSG-TP-II randomized clinical trial is, to our knowledge, the first prospective trial comparing 2 neoadjuvant de-escalation treatments in HR-positive/ERBB2-positive EBC and demonstrated an excellent pCR rate after 12 weeks of paclitaxel plus trastuzumab and pertuzumab that was clearly superior to the pCR rate after ET plus trastuzumab and pertuzumab. ClinicalTrials.gov Identifier: NCT03272477.
    Journal • Clinical
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • ER positive • HR positive • PGR positive • PGR positive + HER-2 positive
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay
    |
    Herceptin (trastuzumab) • paclitaxel • tamoxifen • Perjeta (pertuzumab)
    almost2years
    GeparPiPPa: Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer (clinicaltrials.gov)
    P2, N=170, Recruiting, German Breast Group | Not yet recruiting --> Recruiting | Trial completion date: Jun 2026 --> Jan 2027 | Initiation date: Jun 2022 --> Jan 2023 | Trial primary completion date: Mar 2026 --> Oct 2026
    Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PGR (Progesterone receptor)
    |
    HER-2 positive • PIK3CA mutation • ER positive + PGR positive • PGR positive • PGR positive + HER-2 positive
    |
    Herceptin (trastuzumab) • tamoxifen • Itovebi (inavolisib) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)
    over2years
    GeparPiPPa: Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer (clinicaltrials.gov)
    P2, N=170, Not yet recruiting, German Breast Group
    New P2 trial • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PGR (Progesterone receptor)
    |
    HER-2 positive • PIK3CA mutation • ER positive + PGR positive • PGR positive • PGR positive + HER-2 positive
    |
    Herceptin (trastuzumab) • tamoxifen • Itovebi (inavolisib) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)